Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis.

Muscle Study Group.

Neurology. 2004 Aug 24;63(4):718-20.

PMID:
15326251
2.

Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis.

Muscle Study Group.

Neurology. 2001 Nov 13;57(9):1566-70. Erratum in: Neurology 2002 Jan 22;58(2):334.

PMID:
11706093
3.

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.

Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.

Clin Ther. 2008 Jun;30(6):1102-12. doi: 10.1016/j.clinthera.2008.06.013.

PMID:
18640466
4.

A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome.

Pritchard J, Gray IA, Idrissova ZR, Lecky BR, Sutton IJ, Swan AV, Willison HJ, Winer JB, Hughes RA.

Neurology. 2003 Nov 11;61(9):1282-4.

PMID:
14610140
5.

Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis.

Pena-Rossi C, Schreiber S, Golubovic G, Mertz-Nielsen A, Panes J, Rachmilewitz D, Shieh MJ, Simanenkov VI, Stanton D, Graffner H.

Aliment Pharmacol Ther. 2008 Sep 15;28(6):758-67.

PMID:
19145731
6.

High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study.

Walter MC, Lochmüller H, Toepfer M, Schlotter B, Reilich P, Schröder M, Müller-Felber W, Pongratz D.

J Neurol. 2000 Jan;247(1):22-8.

PMID:
10701893
7.

Pilot trial of etanercept in the treatment of inclusion-body myositis.

Barohn RJ, Herbelin L, Kissel JT, King W, McVey AL, Saperstein DS, Mendell JR.

Neurology. 2006 Jan 24;66(2 Suppl 1):S123-4.

PMID:
16432140
9.

A pilot randomized trial of oxandrolone in inclusion body myositis.

Rutkove SB, Parker RA, Nardin RA, Connolly CE, Felice KJ, Raynor EM.

Neurology. 2002 Apr 9;58(7):1081-7.

PMID:
11940697
10.

Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.

Minagara A, Murray TJ; PROOF Study Investigators.

Curr Med Res Opin. 2008 Apr;24(4):1049-55. doi: 10.1185/030079908X280545 . Epub 2008 Feb 29.

PMID:
18315940
11.

Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.

Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D.

Mult Scler. 2009 Aug;15(8):965-76. doi: 10.1177/1352458509105229. Epub 2009 May 22.

PMID:
19465443
12.

A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM.

Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E.

Neurology. 2001 Feb 13;56(3):323-7.

PMID:
11171896
13.

Alleviating flu-like symptoms with dose titration and analgesics in MS patients on intramuscular interferon beta-1a therapy: a pilot study.

Brandes DW, Bigley K, Hornstein W, Cohen H, Au W, Shubin R.

Curr Med Res Opin. 2007 Jul;23(7):1667-72.

PMID:
17588298
14.

Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity.

Jackson CE, Barohn RJ, Gronseth G, Pandya S, Herbelin L; Muscle Study Group.

Muscle Nerve. 2008 Apr;37(4):473-6. doi: 10.1002/mus.20958.

PMID:
18236463
15.

Dose titration of intramuscular interferon beta-1a reduces the severity and incidence of flu-like symptoms during treatment initiation.

Matson MA, Zimmerman TR Jr, Tuccillo D, Tang Y, Deykin A.

Curr Med Res Opin. 2011 Dec;27(12):2271-8. doi: 10.1185/03007995.2011.630720. Epub 2011 Oct 28.

PMID:
21988668
16.

Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.

Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.

Arch Neurol. 2008 Feb;65(2):199-204. Epub 2007 Dec 10.

PMID:
18071030
19.
20.

Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo.

Badrising UA, Maat-Schieman ML, Ferrari MD, Zwinderman AH, Wessels JA, Breedveld FC, van Doorn PA, van Engelen BG, Hoogendijk JE, Höweler CJ, de Jager AE, Jennekens FG, Koehler PJ, de Visser M, Viddeleer A, Verschuuren JJ, Wintzen AR.

Ann Neurol. 2002 Mar;51(3):369-72.

PMID:
11891832

Supplemental Content

Support Center